Answers are grounded in this paper and cite their sources.
The FACT-B is appropriate for use in oncology clinical trials, as well as in clinical practice. It demonstrates ease of administration, brevity, reliability, validity, and sensitivity to change.
No takes yet. Share an insight, caveat, or question.
Brady et al. (1997) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: